Table 1.
Summary of reviewed studies
| Reference | Design | No. of patients | Mean age at start cidodovir (range) | Adults (A)/children (C)a | Type adult/juvenile papillomatosisb | Gender male (M)/female (F) |
|---|---|---|---|---|---|---|
| Pudszuhn et al. [48] | Case series | 10 | 45 (2–74) | 8 A/2 C | 7 AO/3 JO | 5 M/5 F |
| Naiman et al. [36] | Case series | 16 | 12 (1–34) | 4 A/12 C | JO | 7 M/9 F |
| Naiman et al. [35] | Case series | 19 | 36 (24–52) | 19 A | AO | 13 M/6 F |
| Chung et al. [12] | Case series | 11 | 7 (N/A) | 11 C | JO | 7 M/4 F |
| Sheahan et al. [50] | Case series | 4 | 8 (3–16) | 4 C | JO | 4 F |
| Pontes et al. [43] | Case series | 10 | 40 (27–58) | 10 A | N/A | N/A |
| Dikkers [20] | Case series | 9 | 36 (22–50) | 9 A | 7 AO/2 JO | 6 M/3 F |
| Wemer et al. [55] | Case report | 1 | 28 | 1 A | N/A | 1 F |
| Palomar et al. [40] | Case report | 1 | 4 | 1 C | JO | 1 M |
| de Bilderling et al. [18] | Case report | 1 | 8 | 1 C | JO | 1 F |
| Askew et al. [3] | Case series | 4 | 10 (8–14) | 4 K | JO | 2 M/2 V |
| Lee et al. [30] | Case series | 16 | 33 (9–68) | 13 A/3 C | 12 AO/4 JO | 12 M/4 F |
| Co et al. [13] | Case series | 5 | 36 (30–43) | 5 A | AO | 1 M/4 F |
| Mandell et al. [32] | Case-control series | 7 (incl. 3 controls) | 7 (1–14) | 4 C | JO | 1 M/3 F |
| Peyton et al. [42] | Case series | 11 | 5 (3–13) | 11 C | JO | N/A |
| Avelino et al. [4] | Case series | 5 | 5 (3–9) | 5 K | JO | 3 M/2 V |
| Naiman et al. [37] | Case series | 26 | 28 (5–56) | 19 A/7 C | 16 AO/10 JO | 15 M/11 F |
| Neumann et al. [39] | Case series | 7 | 48 (5–70) | 6 A/1 C | 5 AO/2 JO | 3 M/4 F |
| Chhetri et al. [11] | Case series | 5 | 5 (1–11) | 5 C | JO | 3 M/2 F |
| Milczuk [33] | Case series | 4 | 4 (3–7) | 4 C | JO | 2 M/2 F |
| Pransky et al. [45] | Case series | 11 | 5 (2–9) | 11 C | JO | 7 M/4 F |
| Akst et al. [1] | Case series | 11 | 7 (2–14) | 11 C | JO | 7 M/4 F |
| Coulombeau et al. [14] | Case series | 26 | 28 (5–56) | 19 A/7 C | 16 AO/10 JO | 15 M/11 F |
| El Hakim et al. [22] | Case series | 2 | 4 (3–4) | 2 C | JO | 1 M/1 F |
| Bielamowicz et al. [6] | Case series | 13 | 47 (18–85) | 13 A | N/A | 9 M/4 F |
| Chhetri et al. [9] | Case series | 5 | 44 (21–62) | 5 A | N/A | 5 M |
| El Aatmani et al. [21] | Case report | 1 | 10 | 1 K | JO | 1 V |
| Pransky et al. [46] | Case series | 10 | 5 (2–9) | 10 C | JO | 8 M/2 F |
| Wilson et al. [56] | Case series | 3 | 41 (30–63) | 3 A | AO | 3 M |
| Pransky et al. [47] | Case series | 5 | 3 (2–5) | 5 C | JO | 4 M/1 F |
| Snoeck et al. [51] | Case series | 17 | 44 (11–77) | 14 A/3 C | N/A | 10 M/7 F |
| Total | 188 | 26 (1–85) | 104 A/84 C | 53 AO/89 JO/46/N/A | 98 M/69 F/21 N/A |
Six articles are shown in italics because of an overlap in patient population. The data of the patients from these articles are not added to the total number of patients
N/A not available
aAdults (above 18 years of age), children (under 18 years of age)
bAdult-onset (AO start of RRP above 18 years of age), Juvenile-onset (JO start of RRP under 18 years of age)